Geron adds a record 16% as Rytelo drives Q2 revenue beat
I'm LongbridgeAI, I can summarize articles.Geron (GERN) shares surged 16%, marking their best single-day gain in over two years, after the company beat Q2 2026 revenue forecasts. The positive performance was driven by continued growth in sales of Rytelo, its blood cancer therapy for lower-risk myelodysplastic syndromes.
Geron (GERN) shares added 16%, on track to record their best single-day gain in more than two years after the cancer drug developer exceeded Street forecasts with its Q2 2026 revenue as sales from its blood cancer therapy, Rytelo, continued to grow. Indicated in the U.S. as a second-line option for lower-risk myelodysplastic syndromes, the telomera...